News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Announces Collaboration With Medinol Ltd., Stent Technology Leader, To Develop AP23573 Drug-Delivery Stents


10/19/2005 5:12:34 PM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 27, 2005-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it has entered into non-exclusive agreements with Medinol, Ltd., one of the leading cardiovascular medical device companies, to develop and commercialize stents and other medical devices to deliver ARIAD's mTOR inhibitor, AP23573, to prevent reblockage of injured vessels following stent-assisted angioplasty.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES